Expression of GPC-3 by HCC cells also can also be used as a therapy, where induction of cytotoxic T lymphocytes, specific to GPC-3, by a vaccine reduces the risk of neoplasm recurrence and increases long-term survival [27,28]—for example, the use of antibodies against GPC-3 as cytotoxin carrying molecules, such as gemcitabine or sorafenib, which are supposed to target HCC cells [29,30], and natural killer (NK) cells specific for GPC-3 [31]. This evidence concerns the gene GPC3 and neoplasm.